1276110-06-5 Usage
Description
HS-173 is an imidazopyridine analog that functions as a potent PI3Kα inhibitor with an IC50 value of 0.8 nM. It is recognized for its antiproliferative activity in various cancer cell lines, including T47D, SK-BR-3, and MCF-7, with respective IC50 values of 0.6, 1.5, and 7.8 μM. HS-173 is notable for its ability to induce apoptosis by arresting the cell cycle at the G2/M phase and activating caspases. Additionally, HS-173 has demonstrated the capability to inhibit VEGF-induced angiogenesis both in vitro and in vivo.
Uses
Used in Pharmaceutical Industry:
HS-173 is used as an anticancer agent for its ability to inhibit the PI3Kα pathway, which plays a crucial role in cell growth and survival. Its high potency and selectivity make it a promising candidate for the development of targeted cancer therapies.
HS-173 is used as an inducer of apoptosis for its capacity to arrest the cell cycle at the G2/M phase and activate caspases, leading to the programmed cell death of cancer cells.
Used in Cancer Research:
HS-173 is utilized as a tool in cancer research to study the mechanisms of action and potential therapeutic applications of PI3Kα inhibitors in various cancer types.
HS-173 is used as an inhibitor of angiogenesis to study its effects on VEGF-induced blood vessel formation, which is a critical process for tumor growth and metastasis.
in vitro
hs-173 inhibited the pi3k signaling pathway, and showed anti-proliferative effects on cancer cells. also, hs-173 induced cell cycle arrest at the g2/m phase and apoptosis. in addition, hs-173 decreased the expression hif-1a and vegf which play an important role in angiogenesis. this effect was confirmed by the suppression of tube formation and migration assay in vitro [1].
in vivo
hs-173 diminished blood vessel formation in the matrigel plug assay in mice. these results suggest that hs-173 has potent anti-angiogenic activity in vivo [1].
references
[1] lee h, jung kh, jeong y, hong s, hong ss. hs-173, a novel phosphatidylinositol 3-kinase (pi3k) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. cancer lett. 2013 jan 1;328(1):152-9.
Check Digit Verification of cas no
The CAS Registry Mumber 1276110-06-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,6,1,1 and 0 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1276110-06:
(9*1)+(8*2)+(7*7)+(6*6)+(5*1)+(4*1)+(3*0)+(2*0)+(1*6)=125
125 % 10 = 5
So 1276110-06-5 is a valid CAS Registry Number.
1276110-06-5Relevant articles and documents
Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis
Kim, Okseon,Jeong, Yujeong,Lee, Hyunseung,Hong, Sun-Sun,Hong, Sungwoo
, p. 2455 - 2466 (2011/06/20)
Phosphatidylinositol 3-kinase α (PI3Kα) is an important regulator of intracellular signaling pathways, controlling remarkably diverse arrays of physiological processes. Because the PI3K pathway is frequently up-regulated in human cancers, the inhibition of PI3Kα can be a promising approach to cancer therapy. In this study, we have designed and synthesized a new series of imidazo[1,2-a]pyridine derivatives as PI3Kα inhibitors through the fragment-growing strategy. By varying groups at the 3- and 6-positions of imidazo[1,2-a]pyridines, we studied the structure-activity relationships (SAR) profiles and identified a series of potent PI3Kα inhibitors. Representative derivatives showed good activity in cellular proliferation and apoptosis assays. Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.
